RBC Capital Increases Gilead Sciences Price Target to $115.00 (GILD)
Research analysts at RBC Capital raised their price objective on shares of Gilead Sciences (NASDAQ:GILD) from $102.00 to $115.00 in a report released on Friday. The firm currently has an “outperform” rating on the stock. RBC Capital’s price target points to a potential upside of 10.62% from the company’s current price.
In other Gilead Sciences news, CFO Robin L. Washington sold 33,556 shares of the stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $95.56, for a total transaction of $3,206,611.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
GILD has been the subject of a number of other recent research reports. Analysts at Cowen and Company raised their price target on shares of Gilead Sciences from $95.00 to $105.00 in a research note on Friday, August 15th. They now have an “outperform” rating on the stock. Separately, analysts at FBR Capital Markets initiated coverage on shares of Gilead Sciences in a research note on Thursday, August 14th. They set an “outperform” rating and a $125.00 price target on the stock. Finally, analysts at Argus initiated coverage on shares of Gilead Sciences in a research note on Monday, August 11th. They set a “buy” rating and a $110.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and twenty-one have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $105.55.
Shares of Gilead Sciences (NASDAQ:GILD) opened at 103.96 on Friday. Gilead Sciences has a 1-year low of $58.50 and a 1-year high of $105.16. The stock’s 50-day moving average is $92. and its 200-day moving average is $82.00. The company has a market cap of $157.2 billion and a P/E ratio of 23.17.
Gilead Sciences (NASDAQ:GILD) last released its earnings data on Wednesday, July 23rd. The company reported $2.36 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.73 by $0.63. The company had revenue of $6.53 billion for the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter in the prior year, the company posted $0.50 earnings per share. The company’s quarterly revenue was up 136.1% on a year-over-year basis. On average, analysts predict that Gilead Sciences will post $8.00 earnings per share for the current fiscal year.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
Receive News & Ratings for Gilead Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.